Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
31 hedge funds and large institutions have $3.58M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
237% more call options, than puts
Call options by funds: $847K | Put options by funds: $251K
0% more funds holding
Funds holding: 31 → 31 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
26% less capital invested
Capital invested by funds: $4.84M → $3.58M (-$1.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$76.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$45.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$40.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$30.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$736K |
| 2 |
State Street
Boston,
Massachusetts
|
-$110K |
| 3 |
VF
Virtu Financial
New York
|
-$51K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$23.8K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
26
Bollard Group
Boston,
Massachusetts
| $1K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
VF
28
Virtu Financial
New York
| – | -$51K | -1,517 | Closed |
|
|
WG
29
Winton Group
London,
United Kingdom
| – | -$23K | -677 | Closed |
|
NBRV Hedge Fund Activity: Q3 2021 in Review
31 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2021, worth a combined $3.58M — down 26% from $4.84M a quarter earlier.
Fund positioning in NBRV was balanced in Q3 2021: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $76.8K. The largest seller was Renaissance Technologies, cutting an estimated $736K.
- 31 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $3.58M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2021, down 26% quarter-over-quarter.
- 3 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2021 and 3 closed out, a net change of 0 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2021 was Millennium Management, an estimated $76.8K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2021 was Renaissance Technologies, an estimated $736K sold.
Based on aggregated 13F filings for Q3 2021.